Annual Cash & Cash Equivalents
$8.55 M
-$9.57 M-52.79%
01 December 2023
Summary:
Plus Therapeutics annual cash & cash equivalents is currently $8.55 million, with the most recent change of -$9.57 million (-52.79%) on 01 December 2023. During the last 3 years, it has risen by +$208.00 thousand (+2.49%). PSTV annual cash & cash equivalents is now -83.76% below its all-time high of $52.67 million, reached on 31 December 2010.PSTV Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$1.22 M
-$3.69 M-75.10%
01 September 2024
Summary:
Plus Therapeutics quarterly cash and cash equivalents is currently $1.22 million, with the most recent change of -$3.69 million (-75.10%) on 01 September 2024. Over the past year, it has dropped by -$7.33 million (-85.70%). PSTV quarterly cash and cash equivalents is now -97.68% below its all-time high of $52.67 million, reached on 31 December 2010.PSTV Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTV Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -85.7% |
| 3 y3 years | +2.5% | -94.3% |
| 5 y5 years | +62.6% | -92.7% |
PSTV Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -53.5% | +2.5% | -94.3% | at low |
| 5 y | 5 years | -53.5% | +62.6% | -94.3% | at low |
| alltime | all time | -83.8% | >+9999.0% | -97.7% | +41.5% |
Plus Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.22 M(-75.1%) |
| June 2024 | - | $4.91 M(+69.3%) |
| Mar 2024 | - | $2.90 M(-66.1%) |
| Dec 2023 | $8.55 M(-52.8%) | $8.55 M(-22.3%) |
| Sept 2023 | - | $11.01 M(+1.0%) |
| June 2023 | - | $10.89 M(-14.4%) |
| Mar 2023 | - | $12.72 M(-29.8%) |
| Dec 2022 | $18.12 M(-1.5%) | $18.12 M(-10.6%) |
| Sept 2022 | - | $20.27 M(+12.0%) |
| June 2022 | - | $18.09 M(-14.8%) |
| Mar 2022 | - | $21.24 M(+15.4%) |
| Dec 2021 | $18.40 M(+120.5%) | $18.40 M(-13.5%) |
| Sept 2021 | - | $21.28 M(+24.0%) |
| June 2021 | - | $17.16 M(+18.8%) |
| Mar 2021 | - | $14.45 M(+73.1%) |
| Dec 2020 | $8.35 M(-52.4%) | $8.35 M(+9.4%) |
| Sept 2020 | - | $7.63 M(-17.7%) |
| June 2020 | - | $9.27 M(-42.3%) |
| Mar 2020 | - | $16.06 M(-8.5%) |
| Dec 2019 | $17.55 M(+233.6%) | $17.55 M(+4.3%) |
| Sept 2019 | - | $16.83 M(+271.6%) |
| June 2019 | - | $4.53 M(+17.0%) |
| Mar 2019 | - | $3.87 M(-26.4%) |
| Dec 2018 | $5.26 M(-44.9%) | $5.26 M(-22.7%) |
| Sept 2018 | - | $6.81 M(+121.0%) |
| June 2018 | - | $3.08 M(-47.8%) |
| Mar 2018 | - | $5.90 M(-38.2%) |
| Dec 2017 | $9.55 M(-24.0%) | $9.55 M(+99.7%) |
| Sept 2017 | - | $4.78 M(-47.0%) |
| June 2017 | - | $9.03 M(+44.3%) |
| Mar 2017 | - | $6.25 M(-50.2%) |
| Dec 2016 | $12.56 M(-12.4%) | $12.56 M(-15.8%) |
| Sept 2016 | - | $14.92 M(-25.5%) |
| June 2016 | - | $20.04 M(+114.2%) |
| Mar 2016 | - | $9.36 M(-34.7%) |
| Dec 2015 | $14.34 M(-1.9%) | $14.34 M(-24.4%) |
| Sept 2015 | - | $18.97 M(-20.4%) |
| June 2015 | - | $23.84 M(+80.6%) |
| Mar 2015 | - | $13.20 M(-9.7%) |
| Dec 2014 | $14.62 M(-5.7%) | $14.62 M(+86.3%) |
| Sept 2014 | - | $7.85 M(-38.5%) |
| June 2014 | - | $12.76 M(-0.3%) |
| Mar 2014 | - | $12.80 M(-17.5%) |
| Dec 2013 | $15.51 M(-39.7%) | $15.51 M(+51.9%) |
| Sept 2013 | - | $10.21 M(-25.1%) |
| June 2013 | - | $13.62 M(-17.0%) |
| Mar 2013 | - | $16.40 M(-36.2%) |
| Dec 2012 | $25.72 M | $25.72 M(+45.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $17.63 M(-31.6%) |
| June 2012 | - | $25.77 M(-25.1%) |
| Mar 2012 | - | $34.40 M(-6.8%) |
| Dec 2011 | $36.92 M(-29.9%) | $36.92 M(-9.5%) |
| Sept 2011 | - | $40.80 M(+22.8%) |
| June 2011 | - | $33.23 M(-22.1%) |
| Mar 2011 | - | $42.65 M(-19.0%) |
| Dec 2010 | $52.67 M(+309.7%) | $52.67 M(+71.4%) |
| Sept 2010 | - | $30.73 M(-19.3%) |
| June 2010 | - | $38.10 M(+68.0%) |
| Mar 2010 | - | $22.68 M(+76.5%) |
| Dec 2009 | $12.85 M(+1.9%) | $12.85 M(-2.2%) |
| Sept 2009 | - | $13.14 M(-5.6%) |
| June 2009 | - | $13.92 M(-10.0%) |
| Mar 2009 | - | $15.47 M(+22.7%) |
| Dec 2008 | $12.61 M(+10.0%) | $12.61 M(-5.8%) |
| Sept 2008 | - | $13.39 M(+151.3%) |
| June 2008 | - | $5.33 M(-33.5%) |
| Mar 2008 | - | $8.01 M(-30.1%) |
| Dec 2007 | $11.46 M(+28.8%) | $11.46 M(-36.1%) |
| Sept 2007 | - | $17.94 M(-21.3%) |
| June 2007 | - | $22.81 M(+5.1%) |
| Mar 2007 | - | $21.70 M(+143.8%) |
| Dec 2006 | $8.90 M(+11.2%) | $8.90 M(-34.6%) |
| Sept 2006 | - | $13.62 M(+472.3%) |
| June 2006 | - | $2.38 M(-65.9%) |
| Mar 2006 | - | $6.99 M(-12.8%) |
| Dec 2005 | $8.01 M(+181.9%) | $8.01 M(+252.0%) |
| Sept 2005 | - | $2.27 M(-26.0%) |
| June 2005 | - | $3.08 M(+256.0%) |
| Mar 2005 | - | $864.00 K(-69.6%) |
| Dec 2004 | $2.84 M(+0.7%) | $2.84 M(-4.9%) |
| Sept 2004 | - | $2.99 M(+42.7%) |
| June 2004 | - | $2.09 M(-37.9%) |
| Mar 2004 | - | $3.37 M(+19.5%) |
| Dec 2003 | $2.82 M(-44.8%) | $2.82 M(+20.1%) |
| Sept 2003 | - | $2.35 M(+12.5%) |
| June 2003 | - | $2.09 M(-17.9%) |
| Mar 2003 | - | $2.54 M(-50.2%) |
| Dec 2002 | $5.11 M(+89.2%) | $5.11 M(+18.7%) |
| Sept 2002 | - | $4.30 M(+24.7%) |
| June 2002 | - | $3.45 M(-3.3%) |
| Mar 2002 | - | $3.57 M(+32.1%) |
| Dec 2001 | $2.70 M(-63.9%) | $2.70 M(-3.1%) |
| Sept 2001 | - | $2.79 M(+2.3%) |
| June 2001 | - | $2.73 M |
| Dec 2000 | $7.48 M(+202.5%) | - |
| Dec 1999 | $2.47 M(+6960.0%) | - |
| Dec 1998 | $35.00 K | - |
FAQ
- What is Plus Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Plus Therapeutics?
- What is Plus Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Plus Therapeutics?
- What is Plus Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Plus Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of PSTV is $8.55 M
What is the all time high annual cash & cash equivalents for Plus Therapeutics?
Plus Therapeutics all-time high annual cash & cash equivalents is $52.67 M
What is Plus Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PSTV is $1.22 M
What is the all time high quarterly cash and cash equivalents for Plus Therapeutics?
Plus Therapeutics all-time high quarterly cash and cash equivalents is $52.67 M
What is Plus Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, PSTV quarterly cash and cash equivalents has changed by -$7.33 M (-85.70%)